

**AMENDMENTS TO THE SPECIFICATION**

**Please replace the paragraph on page 4, lines 12-16 with the following amended paragraph:**

FIG. 1 shows comparison of the amino acid sequence of the invention (**OAF065s; SEQ ID NO:11**) and that of TNF receptor family. hTNFR1 represents human necrosis factor receptor 1 (**SEQ ID NO:12**), hTNFR2 represents human necrosis factor receptor 2 (**SEQ ID NO:13**), hNGFR represents human nerve growth factor receptor (**SEQ ID NO:14**), and hFas represents human Fas (**SEQ ID NO:15**) in this figure.

**Please replace the paragraph on page 39, lines 8-15 with the following amended paragraph:**

That is, compared with amino acid sequences of the polypeptide of the invention (**OAF065s; SEQ ID NO:11**) and other members of TNF receptor family i.e. human necrosis factor receptor 1 (hTNFR1; **SEQ ID NO:12**), human necrosis factor receptor 2 (hTNFR2; **SEQ ID NO:13**), human nerve growth factor receptor (hNGFR; **SEQ ID NO:14**), and human Fas (hFas; **SEQ ID NO:15**), it was revealed that the polypeptides (OAF065s) of the invention are type-I membrane protein and they have extracellular Cys rich region which commonly exists in the TNF (Tumor necrosis factor) receptor family in FIG. 1.

**Please replace the Sequence Listing filed February 10, 2004, with the Sequence Listing attached herewith.**